Biofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ Rules

October 31, 2023 8:01 AM

WOBURN, MA / ACCESSWIRE / October 31, 2023 / Biofrontera Inc. (NASDAQ:BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the commercialization of dermatologic products, entered into a securities purchase agreement with a certain institutional investor, pursuant to which the Company agreed to issue and sell to the investor an aggregate of 1,205,000 shares of its common stock (or common stock equivalents in lieu...

Read more

AmplifyBio and Vector BioMed Partner to Manufacture Plasmids and Share Capabilities that Enhance the Safety and Scalability of Lentiviral-based Gene Therapeutics

October 31, 2023 7:00 AM

WEST JEFFERSON, OH and GAITHERSBURG, MD / ACCESSWIRE / October 31, 2023 / AmplifyBio, a leading service provider for the commercialization of advanced modality therapeutics, and Vector BioMed, a biomanufacturing company specializing in the manufacture of lentiviral vectors, announced a strategic partnership that aims to accelerate the development of lentiviral vector-based gene therapeutics. This collaboration brings together two industry...

Read more

Ondine Biomedical Inc Announces Steriwave use Expanded Following Successful Pilot

October 31, 2023 5:40 AM

· Alberta Health Services has expanded its use of Steriwave nasal photodisinfection to reduce the incidence of surgical site infections (SSIs) in orthopedic surgery following a successful pilot at the Mazankowski Alberta Heart Institute.· SSIs, the most common of healthcare-associated infections (HAIs), are a significant burden to healthcare systems as well as to patients, with the estimated cost of a prosthetic hip or knee infection ranging...

Read more

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

October 31, 2023 3:00 AM

LONDON, UK / ACCESSWIRE / October 31, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 31 October 2023 consists of 1,153,065,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the Company is 1,153,065,988.The figure of...

Read more

EvokAI Creative Labs Receives CE Mark Approval for Its MDM Flex Sensor to Transform the Management of Parkinson's Disease

October 30, 2023 10:10 AM

VANCOUVER, BC / ACCESSWORE / October 30, 2023 / EvokAI Creative Labs Inc. (TSXV:OKAI)(OTCQB:OKAIF) ("EvokAI" or the "Company"), a leading MedTech AI-powered company dedicated to the development of transformational and innovative technologies for the healthcare sector, is pleased to announce that its latest technology "MDM Flex Sensor" has received the CE Mark approval, a significant milestone that paves the way for further advancements in the...

Read more

Petros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)

October 30, 2023 9:15 AM

New AI/machine learning tool designed to help potential users more effectively self-select in the effort to make STENDRA the first erectile dysfunction (ED) medication available OTCPetros in discussions with third-party technology partnersNEW YORK, NY / ACCESSWIRE / October 30, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), ), a company focused on expanding consumer access to medication through over-the- counter (OTC) drug development...

Read more

Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil

October 30, 2023 1:20 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 30,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, announces the signature of a partnership with Innovation...

Read more

Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel

October 27, 2023 5:15 PM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 27, 2023 / Biophytis SA (NASDAQCM:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, announces that it has received a notice of delisting from...

Read more

Vibrant America Secures CAP Re-Accreditation, Upholding Excellence in Diagnostic Testing Standards

October 27, 2023 9:15 AM

Vibrant America Achieves Seven-Year Re-Accreditation Milestone from the College of American Pathologists (CAP)SANTA CLARA, CA / ACCESSWIRE / October 27, 2023 / Vibrant America announced its successful re-accreditation by the College of American Pathologists (CAP). This distinction is significant in the lab testing industry, where such accreditation is rare. Even more notable, Vibrant has upheld this standard of excellence for the past seven...

Read more

Edesa Biotech to Present at Dermatology Drug Development Summit

October 26, 2023 4:05 PM

TORONTO, ON / ACCESSWIRE / October 26, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to present at the 7th Annual Dermatology Drug Development Summit in Boston, Mass. on November 1, 2023 at 2:10 p.m. ET.Dr. Nijhawan is expected to present, among other topics, a regulatory pathway...

Read more

Dermata Therapeutics Completes Start-Up Activities to Support DMT310 Phase 3 STAR-1 Acne Trial

October 26, 2023 9:00 AM

- Dermata is prepared to initiate DMT310 Phase 3 STAR-1 clinical trial by the end of 2023 -- Investigational sites have been selected -- Clinical trial materials are ready to be shipped to investigational sites -SAN DIEGO, CA / ACCESSWIRE / October 26, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin...

Read more

enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate Update

October 26, 2023 8:05 AM

- $51.4 million cash on hand sufficient to fund current operations, including multiple value driving milestones, through the end of 2025- Achieved full enrollment for VenoValve® U.S. pivotal trial- Expedited development plan for the enVVe® transcatheter-based replacement venous valveIRVINE, CA / ACCESSWIRE / October 26, 2023 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the...

Read more

Seraxis Announces Publication of Preclinical Data for a Novel Islet Replacement Therapy and Clinical Candidate SR-02 for Insulin-Requiring Diabetes; Oral Presentation at IPITA

October 26, 2023 8:00 AM

Manuscript describes the unique character of a pancreatic endocrine cell population derived from a non-pluripotent stem cell that closely resembles native islets in composition and in vivo function. Dr. William Rust, CEO of Seraxis, will deliver a lecture at the IPITA-IXA-CTRMS Joint Congress on October 29 at 10:00 a.m. in San Diego entitled "Novel stem cell-derived islet-like clusters potently control rodent blood glycemia". Seraxis will be...

Read more

BioInvent International AB: Interim report January–September 2023

October 26, 2023 3:20 AM

LUND, SE / ACCESSWIRE / October 26, 2023 / BioInvent International (STO:BINV)"In the third quarter of 2023, BioInvent achieved a significant landmark with the recruitment of the first patient to the BI-1808 single agent Phase 2a study. BI-1808 can potentially become a novel checkpoint inhibitor and thus play an important role in the context of immune oncology. BioInvent is leading the field of companies aiming to unlock the value of TNFR2 in...

Read more

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech’s ARDS Drug

October 25, 2023 9:10 AM

TORONTO, ON / ACCESSWIRE / October 25, 2023 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that Health Canada has approved the company's proposal to harmonize clinical trial designs in the U.S. and Canada for an ongoing Phase 3 study of EB05 (paridiprubart). Edesa's monoclonal antibody is currently being evaluated as a treatment for Acute...

Read more

Invitation to Presentation of BioInvent’s Interim Report January - September 2023

October 25, 2023 8:15 AM

LUND, SWEDEN / ACCESSWIRE / October 25, 2023 / BioInvent International (STO:BINV) BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts and the press to a presentation of the interim report January- September 2023 at 2:00 pm on Thursday October 26. The report will be published at 8:00 am CET the same day.BioInvent's CEO Martin Welschof will present the report together with CFO Stefan Ericsson. The...

Read more

MorphoSys Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023

October 25, 2023 5:10 AM

Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 million (€ 21.5 million)Preliminary Gross Margin for Monjuvi U.S. net product sales for Q3 2023 of 65%Anticipate full year 2023 Monjuvi U.S. net product sales to be US$ 85-95 million and full year gross margin for Monjuvi U.S. net product sales to be approximately 75%MUNICH, GERMANY / ACCESSWIRE / October 25, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today reported preliminary...

Read more

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

October 24, 2023 4:15 PM

PARIS, FRANCE / ACCESSWIRE / October 24, 2023 / Abivax SA (Euronext Paris:FR0012333284 - ABVX) (" Abivax " or the " Company "), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases, today announced the closing of its previously announced initial public offering on the Nasdaq Global Market by...

Read more

CytoMed Therapeutics Adds to its Intellectual Portfolio After Securing Chinese Patent for its Licensed iPSC-Based Technology

October 24, 2023 1:00 PM

SINGAPORE / ACCESSWIRE / October 24, 2023 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company focused on utilizing its licensed proprietary tech to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced its exclusively licensed induced pluripotent stem call (iPSC)-based technology has been granted a patent by the China National...

Read more

BioStem Technologies Announces Opening of First Clinical Site for Diabetic Foot Ulcer Study

October 24, 2023 8:30 AM

Study to support differentiated efficacy of Vendaje® structural tissue allograftPOMPANO BEACH, FL / ACCESSWIRE / October 24, 2023 / BioStem Technologies Inc. (OTC PINK:BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics for advanced wound care, today announced that the first site is now fully opened for its clinical trial, evaluating the Vendaje® tissue...

Read more